Evidence map›Paper›PMID 35973139›Full record

ArticleThe American journal of gastroenterology2022

Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.

Phillip Gu, Jiyu Luo, Jihoon Kim, Paulina Paul, Berkeley Limketkai, Jenny S Sauk, Sunhee Park, Nimisha Parekh, Kai Zheng, Vivek Rudrapatna and 14 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Obesity: An Overlooked Factor in Inflammatory Bowel Disease.International journal of molecular sciences · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 1 country.

Phillip GuKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical System, Los Angeles, California, USA.
Jiyu LuoDivision of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, UC San Diego, La Jolla, California, USA.
Jihoon KimDivision of Biomedical Informatics, Department of Medicine, UC San Diego, La Jolla, California, USA.
Paulina PaulDivision of Biomedical Informatics, Department of Medicine, UC San Diego, La Jolla, California, USA.
Berkeley LimketkaiVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, UC Los Angeles, Los Angeles, California, USA.
Jenny S SaukVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, UC Los Angeles, Los Angeles, California, USA.
Sunhee ParkDivision of Gastroenterology, Department of Medicine, UC Irvine, Orange, California, USA.
Nimisha ParekhDivision of Gastroenterology, Department of Medicine, UC Irvine, Orange, California, USA.
Kai ZhengDepartment of Informatics, Donald Bren School of Information and Computer Sciences, UC Irvine, Orange, California, USA.
Vivek RudrapatnaDivision of Gastroenterology, Department of Medicine, UC San Francisco, California, USA.
Gaurav SyalKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical System, Los Angeles, California, USA.
Christina HaKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical System, Los Angeles, California, USA.
Dermot P McGovernKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical System, Los Angeles, California, USA.
Gil Y MelmedKarsh Division of Gastroenterology and Hepatology, Department of Medicine, Cedars-Sinai Medical System, Los Angeles, California, USA.
Phillip FleshnerDivision of Colorectal Surgery, Department of Surgery, Cedars-Sinai Medical System, Los Angeles, California, USA.
Samuel EisensteinDivision of Colon and Rectal Surgery, Department of Surgery, UC San Diego, La Jolla, California, USA.
Sonia RamamoorthyDivision of Colon and Rectal Surgery, Department of Surgery, UC San Diego, La Jolla, California, USA.
Parambir S DulaiDivision of Gastroenterology, Department of Medicine, UC San Diego, La Jolla, California, USA.
Brigid S BolandDivision of Gastroenterology, Department of Medicine, UC San Diego, La Jolla, California, USA.
Eduardo GrunvaldDivision of General Internal Medicine, Department of Medicine, UC San Diego, La Jolla, California, USA.
Uma MahadevanDivision of Gastroenterology, Department of Medicine, UC San Francisco, California, USA.
Lucila Ohno-MachadoDivision of Biomedical Informatics, Department of Medicine, UC San Diego, La Jolla, California, USA.
William J SandbornDivision of Gastroenterology, Department of Medicine, UC San Diego, La Jolla, California, USA.
Siddharth SinghDivision of Biomedical Informatics, Department of Medicine, UC San Diego, La Jolla, California, USA.
Cedars-Sinai Medical Center · USUniversity of California, San Diego · USUniversity of California, Irvine · USUniversity of California, Los Angeles · USUniversity of California, San Francisco · US

Funding

California Precision Medicine Research Program ConsortiumOT2OD026552 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ANTON-CULVER, HODA A, OHNO-MACHADO, LUCILA · 2018 to 2023
$73.4M
RADx-Rad Discoveries & Data: Consortium Coordination Center Program OrganizationU24LM013755 · NLM · YALE UNIVERSITY · PI ARONOFF-SPENCER, ELIAH S, OHNO-MACHADO, LUCILA · 2021 to 2023
$23.3M
Protecting Privacy and Facilitating Shared Access of Clinical and Genetic Data of Special PopulationsR01HL136835 · NHLBI · YALE UNIVERSITY · PI OHNO-MACHADO, LUCILA · 2018 to 2022
$6.5M
iAGREE: A Multi-Center, Networked Patient Consent StudyR01HG011066 · NHGRI · YALE UNIVERSITY · PI OHNO-MACHADO, LUCILA · 2020 to 2024
$4.2M
Comparative effectiveness research in Hispanic patients with inflammatory bowel diseasesR01DK135937 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Siddharth Singh · 2024 to 2026
$1.9M
Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel DiseasesK23DK117058 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SINGH, SIDDHARTH · 2018 to 2022
$971k
Predicting Short- and Long-term Risk of Serious Infections in Older Patients with Inflammatory Bowel DiseasesR03DK129631 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SINGH, SIDDHARTH · 2021 to 2022
$203k
NHGRI NIH HHS R01 HG011066NHLBI NIH HHS R01 HL136835NIDDK NIH HHS K23 DK117058NIDDK NIH HHS R01 DK135937NIDDK NIH HHS R03 DK129631NIH HHS OT2 OD026552NLM NIH HHS U24 LM013755
6 · The paper itself

Abstract

introductionObesity is variably associated with treatment response in biologic-treated patients with inflammatory bowel diseases (IBD). We evaluated the association between obesity and risk of hospitalization, surgery, or serious infections in patients with IBD in new users of biologic agents in a large, multicenter, electronic health record (EHR)-based cohort (CA-IBD).

methodsWe created an EHR-based cohort of adult patients with IBD who were new users of biologic agents (tumor necrosis factor [TNF-α] antagonists, ustekinumab, and vedolizumab) between January 1, 2010, and June 30, 2017, from 5 health systems in California. Patients were classified as those with normal body mass index (BMI), overweight, or obese based on the World Health Organization classification. We compared the risk of all-cause hospitalization, IBD-related surgery, or serious infections among patients with obesity vs those overweight vs those with normal BMI, using Cox proportional hazard analyses, adjusting for baseline demographic, disease, and treatment characteristics.

resultsOf 3,038 biologic-treated patients with IBD (69% with Crohn's disease and 76% on TNF-α antagonists), 28.2% (n = 858) were overweight, and 13.7% (n = 416) were obese. On a follow-up after biologic initiation, obesity was not associated with an increased risk of hospitalization (adjusted hazard ratio [aHR] vs normal BMI, 0.90; [95% confidence interval, 0.72-1.13]); IBD-related surgery (aHR, 0.62 [0.31-1.22]); or serious infection (aHR, 1.11 [0.73-1.71]). Similar results were observed on stratified analysis by disease phenotype (Crohn's disease vs ulcerative colitis) and index biologic therapy (TNF-α antagonists vs non-TNF-α antagonists). DISCUSSION: In a multicenter, EHR-based cohort of biologic-treated patients with IBD, obesity was not associated with hospitalization, surgery, or serious infections. Further studies examining the effect of visceral obesity on patient-reported and endoscopic outcomes are needed.

Indexed as

Biological ProductsColitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesCohort StudiesHospitalizationHumansInfliximabObesityOverweightRetrospective StudiesTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsUstekinumabBiological ProductsInfliximabTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsUstekinumab

Identifiers

PMID35973139
PMCPMC13398086
OpenAlexW4281663526

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.